Rapid production of COVID-19 subunit vaccine candidates and their immunogenicity evaluation in pigs.
Int J Biol Macromol
; 272(Pt 1): 132798, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38838896
ABSTRACT
The emergence of various variants of concern (VOCs) necessitates the development of more efficient vaccines for COVID-19. In this study, we established a rapid and robust production platform for a novel subunit vaccine candidate based on eukaryotic HEK-293 T cells. The immunogenicity of the vaccine candidate was evaluated in pigs. The results demonstrated that the pseudovirus neutralizing antibody (pNAb) titers reached 7751 and 306 for the SARS-CoV-2 Delta and Omicron variants, respectively, after the first boost. Subsequently, pNAb titers further increased to 10,201 and 1350, respectively, after the second boost. Additionally, ELISPOT analysis revealed a robust T-cell response characterized by IFN-γ (171 SFCs/106 cells) and IL-2 (101 SFCs/106 cells) production. Our study demonstrates that a vaccine candidate based on the Delta variant spike protein may provide strong and broad protection against the prototype SARS-CoV-2 and VOCs. Moreover, the strategy for the efficient and stable expression of recombinant proteins utilizing HEK-293 T cells can be employed as a universal platform for future vaccine development.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas de Subunidades Antigênicas
/
Anticorpos Neutralizantes
/
Glicoproteína da Espícula de Coronavírus
/
Vacinas contra COVID-19
/
SARS-CoV-2
/
COVID-19
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article